OPM-101

OPM-101 is a first-in-class, selective, and potent small molecule inhibitor of the receptor-interacting serine/threonine-protein kinase 2 (RIPK2) pathway. It is designed to modulate pro-inflammatory signal transmission driven by RIPK2, which plays a key role in the regulation of immune responses and inflammatory processes. By inhibiting RIPK2, OPM-101 demonstrates immunomodulatory effects, including robust and sustained inhibition of TNFα production. OPM-101 is being developed by Oncodesign Precision Medicine for oral administration, with the primary indications in chronic inflammatory diseases such as inflammatory bowel disease (IBD) and in immuno-oncology. In preclinical cancer models, OPM-101 enhanced the efficacy of anti-PD-1 antibody therapy, resensitizing tumors to immunotherapy and promoting durable anti-tumor responses via increased tumor antigen presentation and CD8+ T cell infiltration. OPM-101 is currently being evaluated in phase 1b/2a clinical trials, including a study in combination with pembrolizumab for advanced melanoma resistant to anti-PD-1 therapy[1][2][3][4][5][7][8][10].

Brand names

OPM-101OPM101OPM 101

Other names

OPM-101OPM101OPM 101